Tag: MDS

A promising avenue is the targeting of CD37, a tetraspanin family member broadly expressed on malignant myeloid blasts but with limited expression on normal hematopoietic stem cells. Debio 1562M,** a second-generation novel antibody-drug conjugate (ADC) developed by Debiopharm, is designed to target CD37 and deliver a potent cytotoxic payload directly to tumor cells. Here, we review the preclinical development, mechanism of action, and therapeutic potential of Debio 1562M in AML and MDS.

During the annual meeting for the American Association for Cancer Research (AACR) meeting held April 25 - 30, 2025 in Chicago, Illinois, Swiss-based Debiopharm presented comprehensive preclinical results for Debio 1562M (see ADC Drugmap) a next-generation Antibody-Drug Conjugate (ADC) targeting the cell surface glycoprotein CD37 being developed to be a potential first in class therapy in Acute Myeloid Leukemia (AML) and Myelodysplastic syndrome (MDS).

Magenta Therapeutics Halts Phase 1/2 Dose Escalation Trial of Conditioning ADC MGTA-117

The University of Minnesota's Institutional Review Board (IRB) and Cancer Protocol Review Committee (CPRC) has granted GT Biopharma (Westlake Village, CA 91362), permission to...

The U.S. Food and Drug Administration (FDA) confirmed today that it has lifted the clinical hold on phase 1 trials of vadastuximab talirine (SGN-CD33A;...